– In a multicentre randomized non‑inferiority trial (CloCeBa), cefazolin achieved non‑inferior clinical efficacy to cloxacillin for MSSA bacteraemia (75% vs 74% meeting a 90‑day composite endpoint).
– Cefazolin was associated with fewer serious adverse events (15% vs 27%) and markedly lower acute kidney injury (AKI) (1% vs 12%).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
